San Diego Life Sciences Roundup: Halozyme, Sophiris, Arena, & More
Plans by Bedford, MA-based Hologic to acquire San Diego’s Gen-Probe, are moving ahead. We’ve got the latest details, along with the rest of the innovation news in San Diego’s biotech, diagnostics, and medical device sectors.
—San Diego’s BioNano Genomics, which is getting ready to introduce its nanoAnalyzer System, has raised almost $11.6 million in a mix of equity, rights, and securities that targets almost $14 million, according to a recent regulatory filing. In a statement issued the same day, the company said it has raised $10 million in a Series B-1 round. Existing investors Battelle Ventures, Domain Associates and Gund Investment participated in the round. The company, founded in 2007 as BioNanomatrix, says its single-molecule imaging technology captures extremely long molecules at high resolution, enabling scientists to visualize an entire genome. BioNano Genomics says its approach should provide the context that has been missing in efforts to make the link between phenotypic variation and genomic variation.
—Sophiris Bio, which moved to San Diego from Canada last year, plans to meet with FDA regulators this summer to determine the design of pivotal clinical trials for an experimental drug intended to treat enlarged prostate glands. Lars Ekman, a Sofinnova Ventures partner who has stepped in as CEO at the company, told me there will likely be two clinical trials, with 500 to 600 patients in each. Sophiris Bio, which currently trades on the Toronto Stock Exchange under the ticker symbol SHS, also will need to raise additional capital for the trials.